Genetic Associations With Toxicity-related Discontinuation of Aromatase Inhibitor Therapy for Breast Cancer

BACKGROUND: Up to 25% of patients discontinue adjuvant aromatase inhibitor (AI) therapy due to intolerable symptoms. Predictors of which patients will be unable to tolerate these medications have not been defined. We hypothesized that inherited variants in candidate genes are associated with treatme...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Henry, N. Lynn, Skaar, Todd C., Dantzer, Jessica, Li, Lang, Kidwell, Kelley, Gersch, Christina, Nguyen, Anne T., Rae, James M., Desta, Zeruesenay, Oesterreich, Steffi, Philips, Santosh, Carpenter, Janet S., Storniolo, Anna M., Stearns, Vered, Hayes, Daniel F., Flockhart, David A.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646626/
https://ncbi.nlm.nih.gov/pubmed/23546553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2504-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares